Veeva Systems Inc. — Q3 FY2022 Form 10-Q
Reporting period: Quarter and nine months ended October 31, 2021; comparisons are with the same periods in 2020. Amounts below are in U.S. dollars unless noted.
Business context
Veeva provides cloud software, data, analytics, and services, primarily to the life sciences industry. It reorganized its product reporting this quarter into Commercial Solutions and R&D Solutions; prior-period product figures were recast, with no change to total revenue. For the nine-month period, R&D Solutions represented 43% of revenue, up from 40% of revenue in FY2021.
Financial highlights
| Metric | Q3 FY2022 | Q3 FY2021 | Nine months FY2022 | Nine months FY2021 |
|---|---|---|---|---|
| Total revenue | $476.1m (+26%) | $377.5m | $1,365.3m (+28%) | $1,068.3m |
| Subscription revenue | $380.7m (+26%) | $302.9m | $1,088.3m (+27%) | $856.7m |
| Professional services and other revenue | $95.4m (+28%) | $74.6m | $277.0m (+31%) | $211.6m |
| Gross margin | 73% | 73% | 73% | 72% |
| Operating income | $132.7m | $101.3m | $385.8m | $279.0m |
| Net income | $105.9m | $97.0m | $330.3m | $277.1m |
| Diluted earnings per share | $0.65 | $0.60 | $2.03 | $1.73 |
| Operating cash flow | $113.0m | $95.4m | $710.4m | $482.9m |
Q3 operating margin was approximately 27.9%, versus 26.8% a year earlier; nine-month operating margin was 28.3%, versus 26.1%. Net income grew more slowly than operating income, reflecting a higher tax provision: the effective tax rate was 20.7% for Q3 and 15.9% year to date, compared with 7.4% and 4.0%, respectively. Management attributed the increase mainly to lower excess tax benefits from equity compensation and higher valuation allowances in certain jurisdictions.
At October 31, 2021, cash and cash equivalents were $1.15bn and short-term investments were $1.20bn, totaling approximately $2.35bn. Current assets were $2.66bn and current liabilities were $536.9m. Total liabilities were $598.1m; the filing reports no borrowings. Nine-month operating cash flow increased to $710.4m. Investing cash outflow was $291.0m, mainly reflecting net purchases of investments; financing cash flow was $6.4m, including cash taxes paid on net-settled employee awards. Stock-based compensation was $172.9m for the nine months.
Changes, outlook, and risks
- Revenue grew across both product areas; nine-month subscription revenue growth included $130m from R&D Solutions and $102m from Commercial Solutions. Professional services demand also rose, particularly for R&D implementations.
- Management expects revenue growth rates to decline over time and operating expenses to rise as it invests in product development, sales, services, and infrastructure. Most employees received a 5% salary increase effective September 1, 2021.
- Management said nine-month operating cash flow represents a significant portion of expected full-year cash flow and expects cash flow to be substantially lower in subsequent quarters of FY2022. It believes current liquidity and operating cash generation will meet needs for at least the next 12 months.
- Approximately $1.037bn of remaining subscription-services performance obligations was expected to be recognized; about 73% was expected within the next 12 months. This is contracted revenue, not a revenue forecast.
- COVID-19 had not materially harmed operating or financial performance to date, but effects remain uncertain. Management expects life sciences companies may reduce sales-representative headcount by roughly 10% over the next one to two years, potentially pressuring CRM demand; demand for virtual-interaction products could benefit.
- Material legal matters include ongoing IQVIA litigation and Veeva counterclaims, and a Medidata trade-secret case. The company says outcomes and potential losses cannot be meaningfully estimated. Its IQVIA counterclaims seek more than $200m plus injunctive relief; this is a claim, not recognized income.
- Key business exposures include reliance on Salesforce for core CRM infrastructure, third-party cloud providers and data suppliers, competition, customer concentration, privacy and security obligations, foreign-exchange and interest-rate risk, and the company’s public-benefit-corporation governance duties. A 100-basis-point rate increase was estimated to reduce investment-portfolio market value by $14m.
Important facts for investors to verify
- Whether subscription growth, renewals, and R&D adoption continue to offset the expected longer-term slowdown in growth and possible CRM pressure from fewer sales representatives.
- How higher hiring, compensation, infrastructure, data-acquisition, and litigation costs affect margins, especially given $172.9m of nine-month stock-based compensation.
- Whether the effective tax rate remains elevated compared with prior-year periods and how that affects GAAP earnings.
- Developments in IQVIA and Medidata cases, including any court rulings, costs, or changes to the currently unquantifiable exposure.
- Changes in cash generation after the unusually strong first nine months, and the value and interest-rate sensitivity of the $1.20bn short-term investment portfolio.